Active Not RecruitingNCT05769153
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
PHASE1 · PHASE2 · 139 planned enrolment
- Countries listed
- 1
- Registry update
- August 27, 2026
Registry Intervention View
sham procedure
Trial registrations containing the exact intervention label sham procedure.
Exact registry label · Not reported
14 linked registrations
No aliases or equivalent products have been inferred.
Topics connected by trial metadata
12 linked registrations report posted results
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →Registered trials
CompletedNCT05811351
A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
PHASE2 · 305 planned enrolment
- Countries listed
- 17
- Registry update
- March 13, 2026
CompletedNCT04777201
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
PHASE3 · 1,036 planned enrolment
- Countries listed
- 27
- Registry update
- October 24, 2025
CompletedNCT03823287
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
PHASE3 · 671 planned enrolment
- Countries listed
- 15
- Registry update
- July 23, 2025
CompletedNCT03823300
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
PHASE3 · 658 planned enrolment
- Countries listed
- 21
- Registry update
- July 11, 2025
TerminatedNCT04049266
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
PHASE2 · PHASE3 · 559 planned enrolment
- Countries listed
- 7
- Registry update
- July 18, 2024
CompletedNCT04964089
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
PHASE3 · 557 planned enrolment
- Countries listed
- 2
- Registry update
- July 3, 2024
CompletedNCT03525613
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
PHASE3 · 637 planned enrolment
- Countries listed
- 14
- Registry update
- July 6, 2023
CompletedNCT03525600
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
PHASE3 · 621 planned enrolment
- Countries listed
- 15
- Registry update
- June 18, 2023
CompletedNCT02484690
A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
PHASE2 · 273 planned enrolment
- Countries listed
- 1
- Registry update
- November 12, 2020
CompletedNCT02462486
Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
PHASE3 · 949 planned enrolment
- Countries listed
- 16
- Registry update
- July 30, 2020
CompletedNCT02462928
A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
PHASE3 · 939 planned enrolment
- Countries listed
- 17
- Registry update
- July 28, 2020
CompletedNCT02181504
A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration
PHASE2 · 25 planned enrolment
- Countries listed
- 1
- Registry update
- April 25, 2017
CompletedNCT02181517
A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
PHASE2 · 25 planned enrolment
- Countries listed
- 1
- Registry update
- May 17, 2016